CRP and irritable bowel syndrome: A relatively large cross-sectional study demonstrated that hsCRP could be a marker for inflammation in Irritable Bowel Syndrome (IBS), another study supported values < 10 mg/L to occur in remissions, and a meta-analysis concluded that CRP seems to be a useful biomarker for endoscopic activity in Irritable Bowel Disease (IBD) patients, but another a meta-analysis concluded that CRP essentially excludes IBD in patients with IBS-like symptoms; therewithal, increased CRP was proposed as a marker for short-term mortality in patients with percutaneous endoscopic gastrostomy [322,323,324].